LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW
Liminatus Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.11+0.07 (+2.30%)
Close on Oct 19, 2026
- Market cap
- $150.52M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$54.39 (−94.59%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $150.52M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 500.71
- Dividend yield
- –
- Free cash flow yield
- -6.63%
Fundamentals
- Net income
- -$12.52M
- EPS, diluted
- -$0.43
- Free cash flow
- -$9.98M
- Book value per share
- $0.01
- Diluted shares
- 48M
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Operating income
-$4.07M
Net income
-$12.52M
EPS, diluted
-$0.43
Free cash flow
–
Reported periodTrailing twelve months